The following trials provide information to treat various types of gastrointestinal diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A randomised, single blind, three-way cross-over, single-centre study to assess the pharmacodynamics (intragastric pH) and pharmacokinetics after repeated oral administration of D961H 20 and 40 mg, and omeprazole 20 mg in Japanese healthy male subjects
- collapse A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg once daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated with Daily Nonsteroidal Anti-inflammatory Drug (NSAIDs) Use
- collapse A Phase I, Open-label, Randomized, Single-center, 2-stage Group Sequential Design, 2-way Crossover Bioequivalence Study Comparing a Fixed-dose Combination Capsule of Esomeprazole 40 mg and Low-dose Acetylsalicylic Acid 325 mg with a Free Combination of Esomeprazole Capsule 40 mg and Low-dose Acetylsalicylic Acid Tablet 325 mg After Single Oral Administration in Healthy Male and Female Subjects
- collapse A Phase I, Open, Randomized, Single-centre, 3-way Crossover Drug-drug Interaction Study of Esomeprazole Capsule 40 mg and Low-dose Acetylsalicylic Acid Tablet 325 mg after 5 days Repeated Oral Administration in Healthy Male and Female Subjects
- collapse A randomised, double-blind, double-dummy, parallel-group, activecontrolled, multicenter study to assess the efficacy and safety of esomeprazole 40 mg q12h i.v. or omeprazole 40 mg q12h iv administration for 5 days in subjects with acute non-variceal upper gastrointestinal bleeding
- collapse A randomized, double-blind, parallel-group, placebo controlled study of esomeprazole iv (bolus infusion of 80 mg followed by a continuous infusion of 8 mg per hour) administered for 72 hours to assess prevention of rebleeding in patients that have undergone successful primary endoscopic haemostasis of a bleeding peptic ulcer – the PUB study
- collapse A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment with Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients with Heartburn and Sleep Disturbances Associated with Gastroesophageal Reflux Disease (GERD)
- collapse A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment with Esomeprazole 20 mg qd to Placebo qd for the Resolution of Upper Abdominal Pain in Patients with Symptomatic Gastroesophageal Reflux Disease (sGERD)
- collapse A 6-month randomized, double-blind, parallel-group, multicentre, placebo-controlled Phase II study to compare anti-asthmatic effect and safety of esomeprazole (Nexium) 40 mg twice daily or 40 mg once daily with placebo in adults with asthma
- collapse Ulcer GU IV (discont NSAID)
